Date | Price Target | Rating | Analyst |
---|---|---|---|
10/4/2024 | $59.00 → $85.00 | Hold → Buy | TD Cowen |
5/30/2024 | $61.00 | Neutral | Robert W. Baird |
5/7/2024 | $99.00 → $59.00 | Buy → Hold | TD Cowen |
5/2/2024 | $85.00 → $60.00 | Buy → Neutral | UBS |
5/1/2024 | Overweight → Neutral | Cantor Fitzgerald | |
5/1/2024 | $87.00 → $60.00 | Outperform → Market Perform | Leerink Partners |
3/6/2024 | $78.00 | Equal Weight | Barclays |
2/26/2024 | $88.00 | Outperform | Leerink Partners |
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
For the third year, CVS Pharmacy is offering 60+ allergy-friendly treats in stores and online McLEAN, Va. and WOONSOCKET, R.I., Oct. 3, 2024 /PRNewswire/ -- FARE (Food Allergy Research & Education), the leading nonprofit organization engaged in food allergy education and advocacy — and the largest provider of charitable support for food allergy research in the U.S. — is partnering with CVS Pharmacy®, a CVS Health® company (NYSE:CVS), for the third consecutive year on the Teal Pumpkin Project, a movement creating a more inclusive Halloween for those with food allergies by offering an expanded selection of non-food treats.
Backed by the strength of CVS Health WOONSOCKET, R.I., Oct. 1, 2024 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE:CVS), today announced our 2025 Medicare products bring together what matters most to our members with a focus on core benefits that support their overall health. We offer value, choice and affordability with our Medicare Advantage (MA) plan options, including $0 monthly plan premium, $0 primary care copay, $0 copay for Tier 1 drugs, plus dental, vision, hearing and SilverSneakers® benefits in every county we serve. We'll also continue to provide an expansive product portfolio — including Medicare Advantage Prescription Drug (MAPD), MA-only, prescription drug plan (PDP), Spe
WOONSOCKET, R.I., Sept. 25, 2024 /PRNewswire/ -- CVS Health® (NYSE:CVS) is actively preparing for Hurricane Helene's landfall in Florida tomorrow. The company's priority is the health and safety of its customers, members and colleagues, and it is committed to providing communities with access to the products and services they need to plan for the storm. CVS Pharmacy® is reaching out to its patients by text message, email and phone to remind them to refill and pick up prescriptions. Stores are also receiving additional supplies of emergency items such as water, batteries and fi
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
13F-HR - CVS HEALTH Corp (0000064803) (Filer)
10-Q - CVS HEALTH Corp (0000064803) (Filer)
8-K - CVS HEALTH Corp (0000064803) (Filer)
3 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
Financial giants have made a conspicuous bullish move on CVS Health. Our analysis of options history for CVS Health (NYSE:CVS) revealed 10 unusual trades. Delving into the details, we found 50% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $374,736, and 7 were calls, valued at $388,184. Expected Price Movements Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $53.0 to $77.5 for CVS Health over the last 3 months. Analyzing Volume & Open Interest Assessing the volume and open interest is a strategic step in options trading. These metr
Across the recent three months, 15 analysts have shared their insights on CVS Health (NYSE:CVS), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 9 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 2 0 0 3M Ago 5 0 6 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $66.13, along with a high estimate of $86.00 and a low estimate of $58.00. Observing
Cantor Fitzgerald analyst Sarah James reiterates CVS Health (NYSE:CVS) with a Neutral and maintains $58 price target.
WOONSOCKET, R.I., Sept. 19, 2024 /PRNewswire/ -- CVS Health (NYSE:CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on November 1, 2024, to holders of record on October 21, 2024. About CVS HealthCVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support i
AM Best has revised the outlook to stable from positive for the Long-Term Issuer Credit Rating (Long-Term ICR) and affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term ICRs of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) (NYSE:CVS). The outlook of the FSR is stable. (Please see below for a detailed listing of the companies.) The Credit Ratings (ratings) of Aetna Health & Life Group reflect its balance sheet strength, which AM Best assesses as very strong, as well as it
Financial Highlights Second quarter total revenues increased to $91.2 billion, up 2.6% compared to the prior yearSecond quarter GAAP diluted EPS of $1.41 and Adjusted EPS of $1.83Generated year-to-date cash flow from operations of $8.0 billion2024 Full-Year Guidance Revised GAAP diluted EPS guidance to a range of $4.95 to $5.20 from at least $5.64Revised Adjusted EPS guidance to a range of $6.40 to $6.65 from at least $7.00Revised cash flow from operations guidance to approximately $9.0 billion from at least $10.5 billionCEO Commentary"We have many points of differentiation that position us to win now and into the future. Our innovation is accelerating more transparent pharmacy reimbursement
TD Cowen upgraded CVS Health from Hold to Buy and set a new price target of $85.00 from $59.00 previously
Robert W. Baird initiated coverage of CVS Health with a rating of Neutral and set a new price target of $61.00
TD Cowen downgraded CVS Health from Buy to Hold and set a new price target of $59.00 from $99.00 previously
WOONSOCKET, R.I., Aug. 14, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Heidi Capozzi will join the company as Executive Vice President, Chief People Officer, effective September 9. She will lead the human resources, labor relations, compensation and benefits, and corporate social responsibility teams who support CVS Health's strategy to build a world of health around every consumer. "Heidi brings a depth of experience and a breadth of industry insights to CVS Health, in particular a proven track record of hiring, building, and growing strong teams and adv
ExtraCare® is now one easy savings membership with two tiers WOONSOCKET, R.I., Jan. 4, 2024 /PRNewswire/ -- CVS Pharmacy®, the retail division of CVS Health® (NYSE:CVS), today announced the evolution of its loyalty program to include two membership tiers: ExtraCare® and ExtraCare Plus™. ExtraCare: The popular, no-fee loyalty program through which members can save hundreds of dollars1 through sale prices, email, and text personalized Deals For You, 2% back in ExtraBucks Rewards® and more, is now simpler and more valuable. ExtraCare will now include benefits previously found wit
American International Group, Inc. (NYSE:AIG) today announced that Roshan Navagamuwa will be joining AIG in December and has been named EVP and Chief Information Officer, effective January 1, 2024. Mr. Navagamuwa will report to Peter Zaffino, AIG Chairman & Chief Executive Officer, and serve on AIG's Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231114592675/en/Roshan Navagamuwa (Photo: Business Wire) As Chief Information Officer, Mr. Navagamuwa will be responsible for AIG's global technology and cybersecurity strategy, managing core infrastructure, technology partnerships and process engineering effo